文献速递主动脉疾病

75岁以上患者行血管腔内动脉瘤修复术与优异的5年生存率相关,提示扩大筛查至该队列可获益

Endovascular aneurysm repair in patients over 75 is associated with excellent 5-year survival, which suggests benefit from expanded screening into this cohort.
PubMed 文献 · J Vasc Surg · 2018-10-06

该研究基于血管质量倡议(VQI)2003至2016年数据,回顾了10,676例75岁以上行择期EVAR的患者,构建5年生存风险模型。风险评分分为四组,5年生存率分别为88%、79%、68%和49%,模型区分度与校准度良好。作者认为风险评分可用于筛选适合扩大筛查的患者,但最高风险组除外。

要点

  • 75岁以上患者择期EVAR的围手术期死亡率仅2.1%(>85岁组)。
  • 风险评分-2至4分、5-8分、9-13分、>13分组的5年生存率分别为88%、79%、68%、49%。
  • 模型C统计量为0.69,校准评分0.99,Brier评分0.15。

核心结论

  • 经过选择的老年患者行择期EVAR的围手术期死亡率可接受。
  • 作者认为风险评分可用于定义适合扩大筛查的患者,但最高风险组除外,以证明取消Medicare覆盖限制的合理性。

研究设计与样本

  • 回顾性队列研究,纳入血管质量倡议(VQI)2003至2016年间10,676例75岁以上行择期EVAR的患者。
  • 使用Cox回归与多变量分数多项式构建5年生存风险模型,并采用自举法进行内部验证。

主要发现

  • 围手术期死亡率随年龄变化,但>85岁组仅为2.1%。
  • 最终风险模型纳入的显著预测因素包括年龄、主动脉直径、血红蛋白、当前吸烟、白人种族、体重指数、肾功能、充血性心力衰竭、他汀使用、慢性阻塞性肺疾病和射血分数。
  • 风险评分范围为-2至33分,均值6.9分,中位数6.0分,呈右偏分布。
  • 风险评分-2至4分、5-8分、9-13分、>13分组的5年生存率分别为88%、79%、68%、49%。
  • 模型区分度与校准度良好:C统计量0.69,校准评分0.99(预测5年生存率0.78 vs 观察5年生存率0.77),Brier评分0.15;内部验证乐观校正后C统计量0.69,校准斜率1.0。

关键数值与推荐

  • 风险评分分组:-2至4分、5-8分、9-13分、>13分。
  • 对应5年生存率:-2至4分组88%,5-8分组79%,9-13分组68%,>13分组49%。

临床怎么用

  • 作者认为风险评分可用于筛选适合扩大筛查的患者,但最高风险组(>13分)除外。
  • 作者认为该评分可证明取消Medicare对75岁以上人群腹主动脉瘤筛查覆盖限制的合理性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular aneurysm repair (EVAR) has decreased the perioperative mortality for patients undergoing abdominal aortic aneurysm repair and has increased the rates of elective aneurysm repair in the elderly. However, Medicare will not cover abdominal aortic aneurysm screening for beneficiaries over 75 years of age. Consequently, abdominal aortic aneurysm treatment in this population depends on incidental detection. Targeted coverage for screening in this population, however, might be beneficial for a subgroup of patients. METHODS: To identify a subset of elderly patients who would potentially benefit from an expanded screening policy, we reviewed all patients greater than 75 years old undergoing elective EVAR in the Vascular Quality Initiative between 2003 and 2016. We used Cox regression with multivariable fractional polynomials to construct a risk model for 5-year survival in elderly patients to identify a subpopulation who might benefit the most from screening and performed internal validation using the bootstrapping technique. RESULTS: We identified 10,676 patients greater than 75 years old undergoing elective EVAR. Although perioperative mortality varied with age, it was only 2.1% in the oldest group of patients (>85 years). Significant predictors included in our final risk model for 5-year survival in the elderly included age, aortic diameter, hemoglobin, current smoking, white race, body mass index, renal function, congestive heart failure, statin use, chronic obstructive pulmonary disease, and ejection fraction. The risk model produced risk scores ranging from a possible -2 to 33. The mean and median risk score were 6.9 and 6.0, respectively, with a right skew. We categorized the risk scores into four groups: -2 to 4 points, 5-8 points, 9-13 points, and more than 13 points, with associated 5-year survivals of 88%, 79%, 68%, and 49%, respectively. The model showed adequate discrimination and calibration, with a C-statistic of 0.69 and a calibration score of 0.99 (predicted 5-year survival of 0.78 compared with an observed 5-year survival of 0.77) and a Brier score of 0.15. Internal validation demonstrated an optimism-corrected C-statistic of 0.69 and a calibration slope of 1.0. CONCLUSIONS: Elective EVAR in elderly patients chosen to undergo repair is associated with acceptable perioperative mortality. Our risk score can be used to define optimal patients for expanded screening into all but the highest risk group based on expected postoperative 5-year survival to justify removing this Medicare coverage restriction.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. O'Donnell TFX, Wade JE, Liang P, et al. Endovascular aneurysm repair in patients over 75 is associated with excellent 5-year survival, which suggests benefit from expanded screening into this cohort. J Vasc Surg. 2018. PMID: 30301692. doi:10.1016/j.jvs.2018.06.205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。